Wire · regulatory
US FDA proposes to withdraw approval for Salerno's cholesterol medication
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 November 2026 · Fusion42 review
The US FDA is proposing to withdraw approval for Salerno Pharmaceuticals' cholesterol medication FloLipid due to repeated failure to file required annual reports, with the company given a chance for a hearing to contest this.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it.
◆ ◆ The Wire takeaway
Regulatory non-compliance by Salerno opens a door for competitors to fill the liquid cholesterol medication gap. You need to watch for similar approval risks that could disrupt supplier stability in your sector.
◆ Coverage
3 sources · 18 Nov 2026
◆ Related on Wire
◆ Topics